

Atty. Docket 127 a TROS 187.0003-00000		Appln. No.	10/798,421	
Applicant	John DEVANE			
Filing Date	March 12, 2004	Group:	3 1/14	

U.S. PATENT DOCUMENTS							
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate	
PS	Publication No. US 2001/0014678 A1	Published 08/16/2001	Cary	514	252.15	02/20/2001	
Ps	Publication No. US 2002/0004065 A1	Published 01/10/2002	Kanios	424	449	01/19/2001	
PS	Publication No. US 2002/0016370 A1	Published 02/07/2002	Shytle, et al.	514	661	06/15/2001	
PS	Publication No. US 2002/0016371 A1	Published 02/07/2002	Shytle, et al.,	514	661	06/15/2001	
Ps	Publication No. US 2002/0103109 A1	Published 08/01/2002	Glick, et al.	514	1	01/18/2002	
P5	6,121,289	09/19/2000	Houdi	514	315	10/09/1998	
DS	6,034,079	03/07/2000	Sanberg, et al.	514	225.8	11/23/1998	

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
99	WO 03/090731	11/6/2003	PCT	A61K	31/05	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
75'	Kachur, et al., "Pharmacological effects of 1,2,3,5,6,10b-hexahydropyrido[2,3g]indolizine, a bridged-nicotine analog," <i>Life Sci., 38</i> (4): 323-330 (1986).					
Ps'	Nordberg, et al., "Uptake and regional distribution of (+)-(R)- and (-)-(S)-N-[methyl-11C]-nicotine in the brains of Rhesus monkey. An attempt to study nicotinic receptors in vivo," J. Neural Transm. Park Dis. Dement. Sect., 1(3): 195-205 (1989).					
PS	Papke, et al., "Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes," J. Pharmacol. Exp. Ther., 297(2): 646-656 (2001).					
PS	Sloan, et al., "Nature of nicotine binding to rat brain P ₂ fraction," Pharmacol. Biochem. Behav., 20(6):899-909 (1984)					

Page 1 of 2

Phyllis Spirack 6/10/04

OMB No. 0651-0011



Atty. Docket No. 2345 0003-00000		Appin. No.	10/798,421	
Applicant	John DEVANE			
Filing Date	March 12, 2004	Group:	unassigned	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
PS	Sloan, et al., "The comparative binding characteristics of nicotinic ligands and their pharmacology," Pharmacol. Biochem. Behav., 30(1):255-267 (1988)				
Py	Targacept press release entitled "Targacept and Dr. Falk Pharma Successfully Complete Phase I Studies of First in Class Drug for Ulcerative Colitis," Winston-Salem, NC, October 1, 2002				
75	Thompson, et al., "Functional bowel disorders and functional abdominal pain," Gut. 45 (Suppl. II): 1143-1147.				
PS	Young, et al. "Mecamylamine: new therapeutic uses and toxicity/risk profile," Clinical Therapeutics 23(4):532-565 (2001)				
PC	Zevin, et al, "Nicotine-mecamylamine interactions," Clin. Pharmacol. Ther., 68(1):58-66 (2000).				
Examiner	Date Considered 3 7.8 00				

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce

403757_1.DOC

Atty. Docket No.	09487.0003-00	AIO	Appln. No. 10	/798,421		
Applicant	John Devane	AUE 1 9 2004 25				
Filing Date	March 12, 2004	MADEMARY	Group: 16	14		
		ADEMAN				
<u> </u>		U.S. PAIEN	T DOCUMENTS	T		
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
				<u> </u>		
		FOREIGN PATI	ENT DOCUMENTS	3		
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
75	WO 00/33812	6/15/2000	PCT			
PS	WO 00/35280	6/22/2000	PCT			
791	WO 00/35279	6/22/2000	PCT			
	OTHER DOCUMEN	NTS (Including Au	thor, Title, Date,	Pertinent F	Pages, Etc.)
PS	Mangel, "Potentiati	on of Colonic Cont	ractility to Cholecy			
13	Braida, et al., "Exc Rat Gastrointestina	itatory and Inhibitor al Transit," <i>Pharma</i>	y Effects of Secon cological Research	d-Generation, Vol. 41, N	on Cholines No. 6, (2000	sterase Inhibitors on 0) pgs. 671-677
	<u> </u>		<i>i</i>	j	1	
Examiner	Thul In	Spir/ac	Date Considered	3/28	8/06	•
th	nitial if reference consideration if not incommunication to application to applic	conformance and r	ot citation is in con not considered. In	formance v	vith MPEP (of this form	609; draw line with next

Patent and Trademark Office - U.S. Department of Commerce

Form PTO 1449